a) Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease. <br/ >b) Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN <br/ >c) Prior history of exposure to imatinib <br/ >d) Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial. <br/ >e) Pregnant or breast feeding women. <br/ >f) Patients unable to swallow oral medicines. <br/ >

a) Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease. <br/ >b) Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN <br/ >c) Prior history of exposure to imatinib <br/ >d) Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial. <br/ >e) Pregnant or breast feeding women. <br/ >f) Patients unable to swallow oral medicines. <br/ >

N/A

N/A

a) Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease. <br/ >b) Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN <br/ >c) Prior history of exposure to imatinib <br/ >d) Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial. <br/ >e) Pregnant or breast feeding women. <br/ >f) Patients unable to swallow oral medicines. <br/ >

a) Abnormal Liver function at baseline, i.e. Serum Bilirubin > 1.5 ULN, ALT and AST > 3 ULN. Upto 5 times in case of chronic liver disease. <br/ >b) Abnormal renal functions at baseline, i.e.. Serum creatinine > 1.5 ULN <br/ >c) Prior history of exposure to imatinib <br/ >d) Any other condition assessed by physiciansâ?? team that will lead to difficulty in carrying out the trial. <br/ >e) Pregnant or breast feeding women. <br/ >f) Patients unable to swallow oral medicines. <br/ >